GlobeNewswire Inc.··NaArriVent Advances Dual-Target Cancer Drug as FDA Clears IND for Novel ADC
ArriVent BioPharma wins FDA clearance for ARR-002, a first-in-class dual-target ADC targeting ovarian and endometrial cancers, with Phase 1 trials expected in H2 2026.
AVBPantibody-drug conjugateovarian cancer